Brigham and Women's Hospital, Harvard Medical School, Boston (United States of America)
0
follower
8
more
presentations
in this session
Tafamidis treatment for transthyretin amyloid cardiomyopathy: results from an open-label, early-access, long-term study extension in an all-comers population